标题
Emerging therapeutic agents for advanced non-small cell lung cancer
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-24
DOI
10.1186/s13045-020-00881-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
- (2019) Alexandros Papachristofilou et al. Journal for ImmunoTherapy of Cancer
- Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
- (2019) W. Victoria Lai et al. EUROPEAN JOURNAL OF CANCER
- 107OCrizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
- (2019) A Shaw et al. ANNALS OF ONCOLOGY
- 180TiPAn open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
- (2019) J Spicer et al. ANNALS OF ONCOLOGY
- Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
- (2019) Amod Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.
- (2019) Jie Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
- (2019) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
- (2019) Amir A. Jazaeri et al. JOURNAL OF CLINICAL ONCOLOGY
- AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.
- (2019) John D. Powderly et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
- (2019) Laura Quan Man Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.
- (2019) Rosalyn A. Juergens et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
- (2019) R. Govindan et al. Journal of Thoracic Oncology
- OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC
- (2019) S. Ramalingam et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
- (2018) Leora Horn et al. CLINICAL CANCER RESEARCH
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
- (2018) Gilberto Lopes et al. JOURNAL OF CLINICAL ONCOLOGY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers HarboringBRAF V600EMutations
- (2018) Lauretta Odogwu et al. ONCOLOGIST
- Precision Targeted Therapy with BLU-667 for RET -Driven Cancers
- (2018) Vivek Subbiah et al. Cancer Discovery
- First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.
- (2018) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer.
- (2018) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.
- (2018) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
- (2018) John Sarantopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.
- (2018) David Michael Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
- (2018) Julie Marie Collins et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies.
- (2018) Jianliang Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
- (2018) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.
- (2018) Vincent K. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours.
- (2018) Udai Banerji et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
- (2018) Erika Paige Hamilton et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.
- (2018) Ignacio Melero Bermejo et al. JOURNAL OF CLINICAL ONCOLOGY
- PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.
- (2018) Daniel A. Vaena et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.
- (2018) Analia Azaro et al. JOURNAL OF CLINICAL ONCOLOGY
- SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
- (2018) Juneko E. Grilley-Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
- (2018) Andreas Nicholas Saltos et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.
- (2018) Jordi Rodon Ahnert et al. JOURNAL OF CLINICAL ONCOLOGY
- First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).
- (2018) Robert Charles Doebele et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).
- (2018) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
- (2018) Pasi A. Janne et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
- (2018) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.
- (2018) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
- (2018) Elizabeth Ruth Plummer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.
- (2018) Sawsan Rashdan et al. JOURNAL OF CLINICAL ONCOLOGY
- PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.
- (2018) Jasgit C. Sachdev et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
- (2018) Alberto Chiappori et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.
- (2018) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer.
- (2018) Arun Rajan et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer.
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
- (2018) Hiroji Iwata et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
- (2018) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
- (2018) G D Demetri et al. ANNALS OF ONCOLOGY
- 1159PPhase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
- (2018) C-C Lin et al. ANNALS OF ONCOLOGY
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
- (2018) Y Wang et al. ANNALS OF ONCOLOGY
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo
- (2018) Srimoyee Ghosh et al. MOLECULAR CANCER THERAPEUTICS
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
- (2017) Sun Min Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- P2.04-013 ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
- (2017) J. Vansteenkiste et al. Journal of Thoracic Oncology
- P2.06-006 Phase I/II Dose Escalation Study of L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
- (2017) Rodryg Ramlau et al. Journal of Thoracic Oncology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
- (2016) V. Velcheti et al. ANNALS OF ONCOLOGY
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
- (2015) Lynette M. Sholl et al. Journal of Thoracic Oncology
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
- (2012) Luis Paz-Ares et al. LANCET ONCOLOGY
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now